Recursion Pharmaceuticals, Inc. RXRX
Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) is a rare genetic drug developer. Its lead program, REC-4881 (MEK1/2 inhibitor), is in Phase 2 for Familial adenomatous polyposis (TUPELO). Its next catalyst on record is REC-4881: Full Phase 1b/2 trial dataset for REC-4881 will be presented at the CGA-IGC Annual Meeting on November 2, 2026. (November 2026).
Upcoming catalysts
- November 2026REC-4881 — Full Phase 1b/2 trial dataset for REC-4881 will be presented at the CGA-IGC Annual Meeting on November 2, 2026.
The full Phase 1b/2 trial dataset will be presented at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting on Monday, November 2 presented by Lisa Boardman, M.D., Mayo Clinic.
Next further out: REC-7735 — Phase 1/2 trial initiation (H2 2026). 8 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| REC-4881 | Familial adenomatous polyposis | small molecule | Phase 2 |
| REC-1245 | Biomarker-enriched solid tumors (RBM39) | small molecule | Phase 1 |
| REC-617 | Solid tumors (CDK7) | small molecule | Phase 1 |
| REC-3565 | B-cell malignancies (MALT1) | small molecule | Phase 1 |
| REC-4539 | Small cell lung cancer (LSD1) | small molecule | Phase 1 |
| REC-7735 | Oncology (PI3Kα H1047R) | small molecule | Phase 1 |
Recent results and decisions
- Oct 15, 2026positive Phase 1 dose escalation: 3 partial responses (2 confirmed) at 45 mg QD or higher in endometrial cancer and HCC, 91.7% disease control rate (n=12); 45 mg QD selected for expansion.
Three partial responses per RECIST 1.1 criteria (2 confirmed, 1 unconfirmed) in heavily pretreated patients with endometrial cancer and hepatocellular carcinoma, all at doses of 45 mg once daily (QD) or higher, with a disease control rate of 91.7% at those doses (n=12).
Filing - Oct 15, 2026positive REC-4881 Phase 1b/2 update shows 47% median reduction in total polyp burden and 55% median reduction in upper GI polyps, with 92% of patients responding in upper GI and durable reductions maintained 12 weeks off treatment.
87% of patients achieved reductions in total polyp burden, with a 47% median reduction in total polyp burden at week 13; In the upper GI tract, 92% of 13 evaluable patients experienced reductions, with 46% achieving equal to or greater than a 65% reduction.
Filing - Oct 15, 2026n/a Sanofi optioned the first development candidate from the collaboration, a potential first-in-class oral small molecule for inflammatory disease, triggering a $10 million milestone payment.
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments under the collaboration to $144 million to date.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.